Document is current
Any future updates will be listed below
-
Authors
Barbanti, Piero https://orcid.org/0000-0002-5670-3755
Aurilia, Cinzia
Fiorentini, Giulia
Egeo, Gabriella
Mascarella, Davide
Proietti, Stefania
Messina, Roberta
Filippi, Massimo
Bonassi, Stefano
Torelli, Paola
Cevoli, Sabina
,
-
Funding
Funding for this research was provided by:
This work was partially supported by the Italian Ministry of Health (Institutional Funding Ricerca Corrente) IRCCS San Raffaele Roma and by Fondazione Italiana Cefalee (FICEF).
- License Information
-
More Information
Article History
Received: 20 August 2025
Revised: 18 September 2025
Accepted: 21 September 2025
First Online: 9 October 2025
Declarations
:
: Piero Barbanti received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Abbvie, Alder, Angelini, Assosalute, Biohaven, DOC Pharma, Eli-Lilly, Fondazione Ricerca e Salute, GSK, Lundbeck, Noema Pharma, Organon, Orion Pharma, Pfizer, Teva, Viatris, Visufarma, and serves as President with Italian Association of Headache Sufferers. Cinzia Aurilia received travel grants from Eli-Lilly, Teva and Pfizer, honoraria from Teva; Giulia Fiorentini have no disclosures to declare, Gabriella Egeo received travel grants and honoraria from Eli-Lilly, TEVA and Lundbeck. Davide Mascarella received travel grants Abbvie, Organon, Teva and educational grant from Eli Lilly and Organon; Stefania Proietti have no disclosures to declare; Roberta Messina received honoraria for speaker activities and participating in advisory boards from Abbvie, Biomedia, Eli Lilly, Lundbeck, Organon, Pfizer and Teva; Massimo Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA); Stefano Bonassi have no disclosures to declare; Paola Torelli received travel grant, honoraria as a speaker, or for participating in advisory boards from Teva, Eli Lilly, Allergan, Organon, Pfizer, Lundbeck and Abbvie; Sabina Cevoli received honoraria for speaker panels from Teva, Abbvie and Organon.
